Vanda Pharmaceuticals Inc. — Form 10-Q
Filed October 29, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
Vanda Pharmaceuticals executed employment agreements with three senior executives on August 20, 2026: Daniel McGuire (SVP, General Counsel, Secretary) at $470,000 base salary plus 45% target bonus; Christos Polymeropoulos (SVP, Medical Director) at $510,000 base salary plus 45% target bonus; and Scott Howell (VP, Chief People Officer) at $456,500 base salary plus 40% target bonus. All agreements are at-will with 12-month severance for involuntary termination, plus bonus and 3-month equity acceleration. Signed by CEO Mihael H. Polymeropoulos.
Why this rating
Three standard executive employment agreements represent ~$1.44M annual base cost (~0.5% of $268.7M market cap). Routine executive hiring/retention documentation; no material change to business operations or strategy.
See more from October 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.